Biotech | September 09, 2021
Eirion Therapeutics mandates HTL Biotechnology to be its exclusive Botulinum API manufacturer.
HTL will build, validate and operate a botulinum manufacturing facility in the US
HTL will build, validate and operate a botulinum manufacturing facility in the US
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
Subscribe To Our Newsletter & Stay Updated
